重组人干扰素α1b雾化吸入治疗婴幼儿呼吸道合胞病毒肺炎的临床研究

Clinical study of Recombinant Human Interferon α1 b atomization inhalation in the treatment of infants with respiratory syncytial virus pneumonia

目的 探讨重组人干扰素α1b雾化吸入治疗婴幼儿呼吸道合胞病毒肺炎的临床疗效.方法 将86例呼吸道合胞病毒肺炎患儿作为研究对象,随机分为对照组和观察组,各43例.对照组：给予常规综合治疗;观察组：在对照组治疗方式基础上,加用重组人干扰素α1b雾化吸入治疗.结果 观察组总有效率为95.35％,对照组总有效率69.77％,两组差异具有统计学意义（P＜0.05）.治疗后,观察组呼吸道合胞病毒肺炎患儿CD3＋水平、CD4＋水平、CD4＋/CD8＋比值和INF水平都高于对照组,且观察组呼吸道合胞病毒肺炎患儿CD8＋水平和IgE水平都低于对照组,差异均有统计学意义（P＜0.01）.观察组患者喘憋缓解的时间（2.47±1.26）d、呼吸率和心率恢复正常的时间（2.43±1.17）d、哮鸣音消失的时间（3.64 ±0.83）d、肺部体征消失的时间（5.46±1.62）d、咳嗽消失的时间（5.56±1.41）d都短于对照组患者喘憋缓解的时间（3.67 ±1.31）d、呼吸率和心率恢复正常的时间（3.58±1.23）d、哮鸣音消失的时间（4.52 ±0.67）d、肺部体征消失的时间（8.54±2.27）d、咳嗽消失的时间（8.90±1.39）d,差异均有统计学意义（P＜0.01）.结论 重组人干扰素α1b雾化吸入治疗婴幼儿呼吸道合胞病毒肺炎疗效确切,可有效改善患儿的免疫功能,防止病毒感染扩散,促进临床症状及体征恢复,缩短病程.

Objective To investigate the clinical effect of Recombinant Human Interferon α1b atomization inhalation in the treatment of infants with respiratory syncytial virus pneumonia.Methods 86 patients of respiratory syncytial virus pneumonia, were randomly divided into control group and observation group, 43 cases in each.Control group was treated with routine comprehensive therapy.Observation group was treated with conventional therapy combined with recombinant human interferon alpha 1 b inhalation therapy.Results The total effective rate of the observation group was 95.35%, the total effective rate of the control group was 69.77% and there was statistically significant difference （P 〈 0.05） between two groups.After treatment, CD3 ±, CD4 ±, CD4 ±/CDs ± ratio, the level of INF of the observation group were higher than those of control group.CD8 ± and IgE level of the observation group were lower than those in the control group, the difference was statistically significant （P 〈 0.01）.Asthmatic remission time （2.47 ± 1.26） d,respiratory rate and heart rate recovery time （2.43 ± 1.17） d, wheeze disappcared time （3.64 ± 0.83） d,the lungs symptom vanishing time （5.46 ± 1.62） d, cough disappeared time （5.56 ± 1.41） d, the observation group were shorter than those of the control group and the difference was statistically significant （P 〈 0.01）.Conclusions There was good curative effect of recombinant human interferon alpha 1b atomization inhalation treatment for infants with respiratory syncytial virus pneumonia.